Oral leukoplakia is a protracted process where patients first develop areas of undifferentiated cells in the oral cavity that can gradually change and become increasingly cancerous. The name leukoplakia comes from the fact that the areas are visible as white spots in the oral cavity. Despite extensive scientific studies concerning the treatment of leukoplakias, successful treatment alternatives are lacking. Regardless of whether one performs surgery or chooses to simply follow the clinical development of untreated leukoplakias, in some cases it is not possible to prevent leukoplakias from turning into squamous cell carcinoma (oral cancer).
Hamlet Pharma intends to investigate whether BAMLET can be developed into a treatment for oral leukoplakia and thereby prevent the transformation to oral squamous cell carcinoma. The company will manufacture substance for oral application and test the clinical effect and safety with a Phase I/II protocol.